Bariatric surgery referrals have fallen sharply since these drugs arrived, and a good deal of that fall is people making a comparison on incomplete information.
Some of them are right to decline surgery. Some of them are declining the more effective and, over a long enough horizon, cheaper option because it involves an operating theatre.
The numbers, side by side
| Sleeve gastrectomy | Gastric bypass | Semaglutide 2.4 mg | Tirzepatide 15 mg | |
|---|---|---|---|---|
| Typical total weight loss | ~25–30% | ~30–35% | ~15% | ~21% |
| Time to reach it | 12–18 months | 12–18 months | 68 weeks | 72 weeks |
| Reversible | No | Effectively no | Yes | Yes |
| Ongoing cost | One-time | One-time | Indefinite | Indefinite |
| Procedural risk | Small but real | Small but real | None | None |
| Nutrient monitoring | Lifelong | Lifelong, stricter | Advisable | Advisable |
Two honest caveats about that table. Surgical figures come from observational cohorts and registries rather than randomised trials against these drugs, and trial populations differ in ways that matter. Direct head-to-head randomised comparisons are only now being run.
~25–30%
Total body weight loss typically achieved with sleeve gastrectomy
~21%
Average weight loss with tirzepatide 15 mg at 72 weeks
SURMOUNT-1, NEJM 2022
Two-thirds
Proportion of lost weight regained within a year of stopping semaglutide
STEP 1 extension
The durability question, which is the real one
Weight loss is not the endpoint. Keeping it off is.
Here the comparison is less favourable to the drugs than the headline percentages suggest. When semaglutide was withdrawn in the STEP 1 extension, participants regained roughly two-thirds of what they had lost within a year, and cardiometabolic improvements reverted alongside it.
Surgery has regain too — it is common, and it is under-discussed by surgeons — but it is generally slower and less complete, because the anatomical change persists whether or not you are engaged with it.
This is the central asymmetry. A GLP-1 works while you take it. Stop, and the biology returns. Surgery keeps working in the background. The implications for anyone thinking about stopping are set out in coming off, year two maintenance and what to take after stopping.
Cost, over a horizon long enough to matter
At US list prices a GLP-1 runs to well over a thousand dollars a month, and self-pay programmes have brought that down substantially without making it trivial — the current picture is in what it costs and cash-pay and direct pricing.
Bariatric surgery is typically quoted at fifteen to twenty-five thousand dollars in the United States, once.
Do the arithmetic over five years and surgery is frequently cheaper, sometimes dramatically. Over one year it is not.
The calculation shifts entirely on coverage. Many plans cover bariatric surgery while excluding weight-loss drugs outright — a genuinely perverse incentive that pushes people toward an irreversible operation because it is the covered option. The coverage landscape is in do you qualify, appealing a prior authorisation, the Medicare fight and when employers drop coverage.
A great many people are choosing an operation because their insurer will pay for an operation. That is not a clinical decision, and everyone involved knows it.
Risk, in both directions
Surgery carries operative mortality now measured in the low tenths of a percent in accredited centres — comparable to gallbladder removal. Complications include leaks, strictures, internal hernias and, over years, nutritional deficiencies requiring lifelong supplementation and monitoring. Bypass in particular alters absorption permanently. There is also a well-documented increase in alcohol use disorder after bypass.
GLP-1s carry no procedural risk. The trade is a side effect profile that is unpleasant rather than dangerous for most people — the timeline is in how long side effects last — plus gallstones, uncommon pancreatitis, and the contraindications that rule out a small group entirely.
Both routes lose muscle. Both require deliberate protein and resistance training to limit it — see the muscle question, the resistance training minimum and the best muscle supplements for GLP-1 users. Drugs designed specifically to protect lean mass are in trials now — see the muscle preservation programmes.
Who each one actually suits
Surgery is the stronger option for a BMI well above 40, for someone who has already lost and regained on medication repeatedly, for people with severe weight-related disease needing the largest and most durable effect available, and — pragmatically — for those who can access it and cannot access a drug indefinitely.
A GLP-1 is the stronger option for a BMI in the 27 to 35 range, for anyone unwilling or unfit to have an operation, for people who want reversibility, for those whose primary target is cardiovascular or renal risk rather than weight alone — see the SELECT data and the kidney indication — and for people with obstructive sleep apnoea, where there is now a licensed route.
Both is increasingly ordinary. GLP-1s are widely used after surgery for insufficient initial loss or later regain, and sometimes before surgery to reduce operative risk. These were never mutually exclusive; they were only ever presented that way.
The question to ask instead
Not “which is better.” Neither is better in the abstract.
The useful question is what you intend to be doing in ten years, and which option you can actually still be doing then. If the honest answer about a medication is that you will be priced out of it in eighteen months, that belongs in the decision now — because a treatment you cannot continue is a treatment whose results you will not keep.